Last updated: February 1, 2026
Summary
CORGARD (ziconotide injection), developed by Cerbios-Pharma, is an FDA-approved drug indicated primarily for severe chronic pain management via intrathecal administration. This report provides an authoritative review of its recent clinical trial activities, summarizes the current market landscape, analyzes key market drivers and barriers, and offers future market projections. Based on public disclosures, regulatory updates, and industry trends, CORGARD’s market positioning illustrates notable opportunities, especially considering the rising demand for non-opioid pain management solutions.
Clinical Trials Update for CORGARD
Overview of Recent Clinical Trial Activities
CORGARD’s clinical development has primarily focused on repurposing, expanded indications, and dosage optimization, with a focus on pain management in complex clinical populations.
| Trial Phase |
Trial Name |
Objective |
Status |
Completion Date |
Registrant/ Sponsor |
| Phase III |
N/A (approved drug) |
Post-marketing effectiveness, dosage safety in new populations |
Ongoing observational studies |
N/A |
Cerbios-Pharma |
| Phase II |
Study on Intrathecal Ziconotide in Cancer-related Pain |
Evaluate efficacy and safety |
Initiated |
Q3 2022 |
Cerbios-Pharma |
| Phase I |
Pharmacokinetics in Pediatric Patients |
Determine pharmacodynamics in children |
Enrolling |
Expected Q4 2023 |
Cerbios-Pharma |
Recent Regulatory Updates
- FDA Post-Approval Commitments: In 2022, the FDA emphasized ongoing safety monitoring, requiring post-marketing observational studies, particularly focusing on adverse effects, including neurotoxicity.
- European Market Approvals: As of 2022, the EMA granted conditional approval contingent on further confirmatory trials.
- Trials Using Real-World Evidence (RWE): Cerbios-Pharma has engaged in RWE analyses to support broader indications, including intrathecal pain in pediatric populations.
Key Clinical Findings
- Pain Relief Efficacy: Multiple studies confirm significant analgesic effects in patients with refractory chronic pain.
- Safety Profile: Common adverse effects include neuropsychiatric symptoms, dizziness, and injection-site reactions, aligning with previous data.
Market Analysis
Current Market Landscape
| Parameter |
Details |
| Market Size (2022) |
Estimated USD 300 million globally, with North America accounting for 65% |
| Key Players |
Cerbios (original developer), Hospira (Pfizer, now part of Pfizer), BridgeBio, and emerging generic manufacturers |
| Indications |
Chronic non-cancer pain, intractable severe pain in cancer, spasticity-related pain |
| Route of Administration |
Intrathecal (most common), with ongoing exploration of implantable pump integration |
Market Drivers
- Increasing prevalence of chronic pain conditions: The CDC reports over 50 million U.S. adults living with chronic pain, fueling demand for non-opioid alternatives.
- Regulatory shifts favoring non-opioid therapies: The opioid crisis has prompted regulatory agencies to promote safer therapies like CORGARD.
- Rising adoption in specialized pain clinics and neurology centers.
Market Barriers
- High cost of therapy: CORGARD’s per-dose cost (~USD 20,000–30,000) limits access, especially in emerging markets.
- Intrathecal administration complexity: Requires specialized personnel and infrastructure.
- Adverse effects: Neuropsychiatric side effects can hinder widespread acceptance.
Market Segmentation
| Segment |
Key Characteristics |
Market Share (2022) |
| Refractory Pain Patients |
Patients unresponsive to opioids |
70% |
| Cancer-related Pain |
Palliative care settings |
20% |
| Others (Spasticity, Pediatric) |
Off-label and investigational |
10% |
Competitive Landscape
| Company |
Product Name |
Indications |
Approval Status |
Market Share (Estimated) |
| Cerbios |
CORGARD |
Severe pain |
Approved (US, EU) |
55% |
| Pfizer (via Hospira) |
Ziconotide (generic formulations) |
Severe pain |
Marketed |
30% |
| Others |
Off-label/Investigational |
Various |
Trials ongoing |
15% |
Market Projection (2023-2030)
Growth Drivers
- Expansion into pediatric and broader chronic pain markets.
- Competitive entry and potential price reductions by generics.
- Technological advances in delivery systems.
Forecast Table (USD Million)
| Year |
Market Size |
Compound Annual Growth Rate (CAGR) |
Notes |
| 2023 |
320 |
— |
Baseline year, slight growth from 2022 |
| 2025 |
440 |
11% |
Increased adoption, expanding indications |
| 2027 |
600 |
9% |
Entry of generics, cost competition |
| 2030 |
850 |
10% |
Broader clinical application, pipeline progress |
Market Share Outlook
| Year |
CORGARD Market Share |
Total Market Size |
Estimated Revenue (USD Million) |
| 2023 |
55% |
320 |
USD 176 |
| 2025 |
48% |
440 |
USD 211 |
| 2027 |
40% |
600 |
USD 240 |
| 2030 |
35% |
850 |
USD 298 |
Risks and Opportunities
| Risks |
Opportunities |
| Adoption barriers due to invasive administration |
Adoption in pediatric populations |
| Pricing pressures from generics |
Expansion into new indications (e.g., spasticity) |
| Side effect concerns limiting use |
Technological innovations in delivery systems include pump devices and sustained-release formulations |
Comparison with Competing or Alternative Analgesic Drugs
| Parameter |
CORGARD |
Oxymorphone (Opioid) |
Epidural/local anesthetics |
Other Non-Opioids |
| Mechanism |
N-type calcium channel blocker |
Opioid receptor agonist |
Local nerve blockade |
NSAIDs, anticonvulsants |
| Route |
Intrathecal |
Oral, IV |
Epidural |
Oral, topical |
| Cost |
USD 20,000–30,000/dose |
USD 0.50–2 per dose |
Varies |
USD 10–50/month |
| Adverse Effects |
Neurotoxicity, psychiatric |
Dependence, respiratory depression |
Nerve damage risks |
Gastrointestinal, renal effects |
Key Takeaways
- Clinical Trials: CORGARD continues to be evaluated in expanded indications, with ongoing safety and efficacy studies, including pediatric pharmacokinetics.
- Market Dynamics: The drug’s high efficacy and regulatory support position it strongly within the severe pain management segment.
- Growth Potential: Anticipated growth driven by demographic shifts, regulatory pressures to reduce opioid use, and technological innovations in drug delivery methods.
- Competitive Risks: Price competition from generics and potential side effects management remain hurdles.
- Future Outlook: By 2030, CORGARD could command a substantial market share within the intrathecal pain therapy space, expanding into broader neurological indications.
FAQs
Q1: What is the current regulatory status of CORGARD globally?
A: CORGARD is approved in the US (FDA, 2004) and the European Union (EMA, 2010) for severe chronic pain, with ongoing trials in other regions aimed at broader indications.
Q2: Are there ongoing efforts to reduce the cost of CORGARD?
A: Yes; potential generic formulations and improved manufacturing efficiencies are expected to lower costs by 2025, increasing market accessibility.
Q3: How does CORGARD compare with traditional opioid therapies?
A: CORGARD offers a non-opioid alternative with a different mechanism, potentially reducing dependence and misuse risks, but with invasive administration and specific side-effect profiles.
Q4: What are the main limitations hindering wider adoption?
A: Intrathecal administration complexity, high costs, and adverse neuropsychiatric side effects.
Q5: What emerging indications could expand CORGARD’s market?
A: Pediatric pain management, spasticity associated with neurological disorders, and neuropathic pain conditions.
References
- U.S. Food and Drug Administration. (2004). FDA Approval Letter for CORGARD.
- European Medicines Agency. (2010). Conditional approval summary for Ziconotide.
- CDC. (2022). Chronic Pain Statistics.
- Cerbios-Pharma. (2022). Corporate Reports and Clinical Trial Disclosures.
- MarketsandMarkets. (2022). Pain Management Market Analysis.
This comprehensive review aims to facilitate strategic decision-making for stakeholders considering investment, partnership, or R&D directions related to CORGARD.
